The need for innovative technologies to accelerate pharmaceutical research and development has never been greater. Seeking to be at the forefront of cutting-edge science, Boehringer Ingelheim is expanding its growing global network of new biological entity (NBE) technology partners to complement its own expertise in research, development and translational medicine.

Scientists at our major research sites, together with our academic and industry partners, are pursuing novel technologies to support therapeutic advances in areas of key unmet medical need. We have the ambition to identify and translate the most promising technology innovations into impactful applications across a broad range of research fields.

Our specific partnering interests offer various opportunities for collaboration:
- Antibody discovery and optimization platforms
- Biologic enabling technologies enhancing our capabilities supporting our therapeutic areas (Oncology, Immunology and Inflammation, CardioMetabolic, Central Nervous System, and Respiratory Diseases)
- New modalities beyond antibody therapy to expand our NBE approaches
- Technologies to enable and accelerate function-driven and first-in-class antibody identification
- New technologies for generation of tool antibodies for the validation of new therapeutic concepts
- Accelerating timelines from tool to lead, lead to drug, as well, as in drug development

Contact:
Dr. Marcio Lasaro
marcio.lasaro@boehringer-ingelheim.com